US group relies on some of the sites being purchased by competitor to produce its own treatments
Danish drugmaker to acquire three manufacturing sites as its controlling shareholder buys US company Catalent
Chief executive says customers very willing to pay for Wegovy from their own pockets
Danish drugmaker reports better than expected earnings for 2023
Danish biotech group Zealand Pharma is developing an alternative obesity treatment to compete with big rivals
Huge demand for weight-loss treatments offers rich rewards but the leading pharma groups will not cede ground easily
Danish manufacturer of Wegovy invests in two start-ups as part of efforts to stay ahead in major new market
Novo Nordisk Foundation is little known outside Nordic countries but is bigger than Wellcome or Gates
The Danish company’s drugs for obesity could have a profound impact on healthcare, society and our relationship with food
Pharma group behind blockbuster drug wants to supersize its market impact
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Danish group has expanded manufacturing capacity but says demand will continue to outstrip supply
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
It follows surge in popularity of Ozempic, which is often used for weight loss
Analysts anticipate that Ozempic and Wegovy will hurt sales at some groups as patients reduce calorie intake
Danish drugmaker behind Wegovy and Ozempic has become Europe’s biggest company
Soaring sales for Novo Nordisk’s products mean market capitalisation now exceeds country’s GDP
Report shows 300% increase in demand for GLP-1 weight loss and diabetes drugs
Danish pharma chief is leading the expansion of blockbuster obesity drug that propelled shares to record high
Shares rise after Danish pharma group launches anti-obesity drug Wegovy in UK
Achievement highlights success of drugmaker on list of companies skewed towards the luxury sector
Low-cost domestic rivals hope to challenge Novo Nordisk in one of world’s biggest markets for anti-obesity medication
A new study bolsters the case that semaglutide is not merely a vanity drug but has a key role to play in treating obesity
